Raphael Pharmaceutical (RAPH) Accumulated Expenses (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Accumulated Expenses of $506000.0 for Q4 2025, up 34.93% on a YoY basis from $375000.0 in Q4 2024, and up 6.53% sequentially from $475000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Accumulated Expenses (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Accumulated Expenses data on file, last reported at $506000.0 in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 34.93% year-over-year to $506000.0; the trailing twelve-month figure through Dec 2025 stood at $506000.0 (up 34.93% YoY), and the FY2025 full-year result was $506000.0, up 34.93% from the prior year.
- Accumulated Expenses advanced to $506000.0 in Q4 2025, from $475000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $537000.0 in Q3 2024 to a low of $25000.0 in Q4 2023.
- A 5-year average of $294500.0 and a median of $323500.0 in 2021 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses soared 2922.22% in 2021 and sank 88.84% in 2023, its largest moves.
- Tracing RAPH's Accumulated Expenses over 5 years: stood at $272000.0 in 2021, then dropped by 17.65% to $224000.0 in 2022, then slumped by 88.84% to $25000.0 in 2023, then surged by 1400.0% to $375000.0 in 2024, then soared by 34.93% to $506000.0 in 2025.
- Business Quant data shows RAPH's Accumulated Expenses at $506000.0 in Q4 2025, $475000.0 in Q3 2025, and $473000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 506,000.00 |
| Sep 30, 2025 | 475,000.00 |
| Jun 30, 2025 | 473,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Dec 31, 2024 | 375,000.00 |
| Sep 30, 2024 | 537,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Mar 31, 2024 | 419,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 438,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | 224,000.00 |
| Sep 30, 2022 | 183,000.00 |
| Jun 30, 2022 | 64,000.00 |
| Mar 31, 2022 | 76,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Sep 30, 2021 | 175,000.00 |
| Dec 31, 2020 | 9,000.00 |